Charles River Laboratories International, Inc. (NYSE:CRL) Stake Boosted by GAMMA Investing LLC

GAMMA Investing LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 61.6% in the 1st quarter, HoldingsChannel reports. The firm owned 1,398 shares of the medical research company’s stock after purchasing an additional 533 shares during the quarter. GAMMA Investing LLC’s holdings in Charles River Laboratories International were worth $210,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Rothschild Investment LLC lifted its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after acquiring an additional 144 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $37,000. GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC lifted its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $157.12 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The company has a 50 day simple moving average of $139.86 and a two-hundred day simple moving average of $152.94. The company has a market capitalization of $7.72 billion, a PE ratio of -241.72, a P/E/G ratio of 5.33 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the business posted $2.27 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on CRL shares. Robert W. Baird lifted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, May 8th. Evercore ISI raised shares of Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price target for the company in a research note on Thursday, May 8th. Redburn Atlantic upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. TD Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price target for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 27th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).